PDEs as drug targets
Phosphodiesterases make good drug targets because they bind small ligands and share similar catalytic mechanisms, while displaying unique architectures around their active sites. This allows for the development of selective inhibitors.
PDE4NPD and the EU
The PDE4NPD Project is one of four neglected parasitic disease (NPD) projects funded under the auspices of the European Commission’s FP7 HEALTH programme.
PDE4NPD and the European Lead Factory team up: parasite PDE up for ultra-HTS against 450,000 compounds
With help of the European Lead Factory, the PDE4NPD project takes the next step towards developing novel drugs against kinetoplastid parasites such as Trypanosoma brucei. Together, PDE4NPD and the EU Lead Factory will screen 450,000 compounds for their potential to inhibit one of the parasite PDEs the project has validated.